# Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer

> **NCT05731726** · PHASE2 · RECRUITING · sponsor: **Zhejiang University** · enrollment: 50 (estimated)

## Conditions studied

- pMMR
- MSS
- MSI-L
- Locally Advanced Rectal Carcinoma

## Interventions

- **DRUG:** Serplulimab
- **DRUG:** Capecitabine
- **DRUG:** Oxaliplatin
- **DRUG:** Celecoxib

## Key facts

- **NCT ID:** NCT05731726
- **Lead sponsor:** Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-02-22
- **Primary completion:** 2026-12-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05731726

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05731726, "Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05731726. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*